Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408224 | 0.93 | DRD4 (0.53) | DRD4SLC6A5CXCR4ACHECHRNB2 | |
| SCHEMBL648168 | 0.91 | SLC6A5 (0.58) | DRD4SLC6A5CXCR4ACHEKDM4E | |
| SCHEMBL648533 | 0.91 | CHRM4 (0.51) | DRD4SLC6A5CXCR4 | |
| SCHEMBL4451000 | 0.91 | ACHE (0.47) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4401689 | 0.88 | DRD4 (0.50) | DRD4SLC6A5CXCR4ACHECHRNB2 | |
| SCHEMBL4453176 | 0.87 | DRD4 (0.53) | DRD4ACHEALDH1A1 | |
| SCHEMBL646987 | 0.86 | SLC6A5 (0.57) | DRD4SLC6A5CXCR4ACHECHRNB2 | |
| SCHEMBL4449419 | 0.86 | MCHR1 (0.53) | ACHEKCNH2 | |
| SCHEMBL4452634 | 0.85 | ACHE (0.48) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4449531 | 0.85 | ACHE (0.58) | DRD4ACHEKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | DRD4 3588/4885SLC6A5 3833/4885CXCR4 1748/4885 |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | DRD4 4704/4885SLC6A5 4782/4885CXCR4 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.